Bergamaschi, Daniele

Daniele Bergamaschi

Daniele Bergamaschi

BSc, PhD
Non clinical Senior Lecturer

Recent and ongoing research projects In my lab we have two lines of research currently going on:

Molecular signalling pathways involved in the epidermal homeostasis. Therefore we are interested in proliferation, adhesion, differentiation, motility, apoptosis and autophagy within the stratified epithelia, by using keratinocytes cell lines, organotypic skin reconstructs and normal epidermis as a model. Our aim is to identify the key molecular signalling pathways that fine tune the homeostatic process in the epidermal epithelia and eventually monitor how they could be deregulated in the specific types of cutaneous malignancies.

In melanoma we are particular interested in the intrinsic resistance of melanocytes to apoptosis during malignant progression. Our research goal is to understand the physiological roles of the key players involved in apoptosis in melanocytes and melanoma cells, with a special regards to the p53 family members signalling pathways somehow altered in melanomas. At this regard we are also exploring the role of cancer stem cells in melanoma.

Bio

After my BSc in Biological Science at the University of Milan in 1994, I studied Cancer Pharmacology at a postgraduate level at the Mario Negri Institute of Pharmacological Research in Milan until 1998. I then moved to London where I worked as a postdoctoral research fellow at the Ludwig Institute for Cancer Research at the UCL with Professor Xin Lu. In November 2005 I was appointed as a Lecturer at the Centre for Cutaneous Research, in the Blizard Institute and in 2009 I was promoted to Senior lecturer.

Research

Apoptosis resistance in melanoma
Molecular signalling pathways involved in the epidermal homeostasis

Melanoma, skin cancer, apoptosis, autophagy, cell cycle, differentiation, gene expression, microRNA.

Publications

Key Publications

Chikh A, Matin RNH, Senatore V, Hufbauer M, Lavery D, Raimondi C, Ostano P, Mello-Grand M, Ghimenti C, Bahta A, Khalaf S, Akgül B, Braun K, Chiorino G, Philpott MP, Harwood CA and Bergamaschi D. iASPP/p63 auto-regulatory feedback loop is required for the homeostasis of stratified epithelia". The EMBO Journal (2011) doi:10.1038/emboj.2011.302.

Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet. 2006 Oct; 38(10):1133-1141.

Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol. 2004 Feb; 24(3):1341-50.

Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003 Apr; 3(4):387-402.

Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE , Lu X. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet. 2003 Feb; 33(2):162-7.

Samuels-Lev Y*, O'Connor DJ*,

Bergamaschi D*, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T, Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001 Oct; 8(4):781-94. ( *equal contribution).


All publications from PubLists

Maurichi A, Miceli R, Camerini T et al. (2014). Prediction of survival in patients with thin melanoma: results from a multi-institution study.. J Clin Oncol Vol.32, (23) 2479-2485.
10.1200/JCO.2013.54.2340
Chikh A, Sanza P, Raimondi C et al. (2014). IASPP is a novel autophagy mudulator in keratinocytes. J Cell Science Vol., (advance online edition) -.
10.1242/​jcs.144816
Bergamaschi D (2014). Is Mcl-1L the new anti-apoptotic effector of B-RAFV(600E) in melanoma?. Exp Dermatol Vol.23, (2) 94-.
10.1111/exd.12312
Matin RN, Chikh A, Chong SL et al. (2013). p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.. J Exp Med Vol.210, (3) 581-603.
10.1084/jem.20121439
BERGAMASCHI D, Wang, Y, Godin-Heymann N et al. (2013). ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells.. Cell Death and Differentiation Vol.20, (4) 1350-9047 525-534.
10.1038/cdd.2013.3
Wang H, Lee S, Nigro CL et al. (2012). NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.. Br J Cancer Vol.106, (8) 1446-1452.
10.1038/bjc.2012.95
Chikh A, Matin RN, Senatore V et al. (2011). iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia.. EMBO J Vol.30, (20) 4261-4273.
10.1038/emboj.2011.302
Llanos S, Royer C, Lu M et al. (2011). Inhibitory Member of the Apoptosis-stimulating Proteins of the p53 Family (iASPP) Interacts with Protein Phosphatase 1 via a Noncanonical Binding Motif.. J Biol Chem. Vol.286, (50) 43039-43044.
10.1074/jbc.M111.270751
Bell HS, Dufes C, O'Prey J et al. (2007). A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J CLIN INVEST Vol.117, (4) 0021-9738 1008-1018.
10.1172/JCI28920
Leverrier S, Bergamaschi D, Ghali L et al. (2007). Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria. APOPTOSIS Vol.12, (3) 1360-8185 549-560.
10.1007/s10495-006-0004-1
Gubser C, Bergamaschi D, Hollinshead M et al. (2007). A new inhibitor of apoptosis from vaccinia virus and eukaryotes.. PLoS Pathog Vol.3, (2) e17-.
10.1371/journal.ppat.0030017
Bergamaschi D, Samuels Y, Sullivan A et al. (2006). iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72 polymorphic p53. NAT GENET Vol.38, (10) 1061-4036 1133-1141.
10.1038/ng1879
Bergamaschi D, Samuels Y, Zhong S et al. (2005). Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation. ONCOGENE Vol.24, (23) 0950-9232 3836-3841.
10.1038/sj.onc.1208535
Zhang WQ, Bergamaschi D, Jin BQ et al. (2005). Posttranslational modifications of p27kip1 determine its binding specificity to different cyclins and cyclin-dependent kinases in vivo. BLOOD Vol.105, (9) 0006-4971 3691-3698.
10.1182/blood-2003-07-2558
Slee EA, Gillotin S, Bergamaschi D et al. (2004). The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization.. Oncogene Vol.23, (56) 0950-9232 9007-9016.
10.1038/sj.onc.1208088
Sullivan A, Syed N, Gasco M et al. (2004). Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo.. Oncogene Vol.23, (19) 0950-9232 3328-3337.
10.1038/sj.onc.1207428
Bergamaschi D, Samuels Y, Jin B et al. (2004). ASPP1 and ASPP2: common activators of p53 family members.. Mol Cell Biol Vol.24, (3) 0270-7306 1341-1350.
10.1128/MCD.24.3.1314-1350.2004
Bergamaschi D, Gasco M, Hiller L et al. (2003). p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.. Cancer Cell Vol.3, (4) 1535-6108 387-402.
10.1016/S1535-6108(03)00079-5
Bergamaschi D, Samuels Y, O'Neil NJ et al. (2003). iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.. Nat Genet Vol.33, (2) 1061-4036 162-167.
10.1038/ng1070
Samuels-Lev Y, O'Connor DJ, Bergamaschi D et al. (2001). ASPP proteins specifically stimulate the apoptotic function of p53.. Mol Cell Vol.8, (4) 1097-2765 781-794.
10.1016/S1097-2765(01)00367-7
Erba E, Bergamaschi D, Bassano L et al. (2001). Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.. Eur J Cancer Vol.37, (1) 0959-8049 97-105.
10.1016/S0959-8049(00)00357-9

Teaching

SSM in dermatology, BMed Science Cutaneous Module,
PBL tutors, SSC2 tutor

Mentor of Y1 and Y2 medical students

PhD Students:

Rubeta NH Matin
Folake Akinduro
Manuela Graf

Contact

Blizard Institute
Barts and The London School of Medicine and Dentistry
Blizard Building
4 Newark Street
London
E1 2AT

+44 (0) 20 7882 2567
This email address is being protected from spambots. You need JavaScript enabled to view it.